Conditions

Subcategories:Axial Spondyloarthritis Clinical Criteria/Guidelines Gout and Crystalline Arthritis Myositis Osteoarthritis and Bone Disorders Other Rheumatic Conditions Pain Syndromes Pediatric Conditions Psoriatic Arthritis Rheumatoid Arthritis Sjögren’s Disease Soft Tissue Pain Systemic Lupus Erythematosus Systemic Sclerosis Vasculitis

Unexpected Benefits of Bisphosphonates after Hip Fracture

Cathleen Colon-Emeric, MD, MHS | February 3, 2012

Recent trials show this bisphosphonates can reduce subsequent hip fractures and mortality, while remaining cost effective.

New Diagnostic Criteria for Axial Spondylarthritis

Ann Kepler | February 3, 2012

New name and classification criteria for ankylosing spondylitis may help with earlier diagnosis and treatment.

Dermatology Case Review

Joseph F. Merola, MD | February 3, 2012

A 64-year-old man with history of type-II diabetes (well controlled on sitagliptin/metformin), hypertension, and dyslipidemia presents with complaints of an increasingly painful left lower-extremity lesion present for two to three months.

Dermatology Case Answer

Joseph F. Merola, MD | February 3, 2012

A Patient’s Perspective on RA

Lisa C. Glavish | February 3, 2012

I was diagnosed in April 2010, at 44 years old, with seropositive RA; the disease rapidly turned my life upside down.

Coding Corner: February’s Coding Challenge

Staff | February 3, 2012

A 62-year-old male patient returns to the office for a followup visit for his gout.

Coding Corner Answer: February’s Coding Challenge

Staff | February 3, 2012

A 62-year-old male patient returns to the office for a followup visit for his gout.

A&R and AC&R Abstracts: Bisphosphonates

Staff | February 3, 2012

Want to learn more about bisphosphonates and fractures? Check out these abstracts from Arthritis & Rheumatism and Arthritis Care & Research.

A Passion for Multidisciplinary Collaboration

Gretchen Henkel | February 3, 2012

Through teamwork, David T. Felson, MD, MPH, has advanced understanding and treatment of rheumatic diseases

Letter: RA Approval for IL-1Ra

William Arend, MD | February 3, 2012

Investors convinced the executives of Synergen that they needed to evaluate IL-1Ra for a disease with a more rapid outcome. RA studies were too slow to yield a quick profit. Thus, they picked sepsis syndrome.